Insights

Rare Disease Focus Aceragen specializes in rare disease biopharmaceuticals, targeting neglected diseases without treatment options, presenting a significant sales opportunity in a niche market segment.

Therapeutic Innovation Aceragen is dedicated to developing novel therapies for rare diseases, offering potential sales opportunities with unique therapeutic options that meet unaddressed patient needs.

Funding Strength With a recent funding injection of $35M, Aceragen showcases financial stability, indicating potential business growth and room for partnership or collaboration opportunities for sales expansion.

Market Differentiation In a landscape with companies like The Medicines Company and Accord Healthcare, Aceragen stands out due to its exclusive focus on rare and orphan diseases, creating a unique selling point and competitive advantage for sales strategies.

Community Engagement Aceragen actively engages in community awareness initiatives and regulatory outreach, signaling a commitment to advocacy and public health, which can be leveraged for building strong customer relationships and sales prospects.

Similar companies to Aceragen

Aceragen Tech Stack

Aceragen uses 8 technology products and services including W3 Total Cache, jQuery CDN, WordPress, and more. Explore Aceragen's tech stack below.

  • W3 Total Cache
    Caching
  • jQuery CDN
    Content Delivery Network
  • WordPress
    Content Management System
  • MySQL
    Database
  • jQuery
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • Gravity Forms
    Web Platform Extensions
  • Nginx
    Web Servers

Media & News

Aceragen's Email Address Formats

Aceragen uses at least 1 format(s):
Aceragen Email FormatsExamplePercentage
FLast@aceragen.comJDoe@aceragen.com
50%
FLast@aceragen.comJDoe@aceragen.com
50%

Frequently Asked Questions

Where is Aceragen's headquarters located?

Minus sign iconPlus sign icon
Aceragen's main headquarters is located at 15 TW Alexander Dr Durham, North Carolina 27709 US. The company has employees across 1 continents, including North America.

What is Aceragen's stock symbol?

Minus sign iconPlus sign icon
Aceragen is a publicly traded company; the company's stock symbol is ACGN.

What is Aceragen's official website and social media links?

Minus sign iconPlus sign icon
Aceragen's official website is aceragen.com and has social profiles on LinkedIn.

What is Aceragen's SIC code NAICS code?

Minus sign iconPlus sign icon
Aceragen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Aceragen have currently?

Minus sign iconPlus sign icon
As of August 2024, Aceragen has approximately 11 employees across 1 continents, including North America. Key team members include Chief Executive Officer: J. T.Chief Financial Officer: A. J.Co-Founder, Scientific Advisor: A. C.. Explore Aceragen's employee directory with LeadIQ.

What industry does Aceragen belong to?

Minus sign iconPlus sign icon
Aceragen operates in the Biotechnology Research industry.

What technology does Aceragen use?

Minus sign iconPlus sign icon
Aceragen's tech stack includes W3 Total CachejQuery CDNWordPressMySQLjQueryOpen GraphGravity FormsNginx.

What is Aceragen's email format?

Minus sign iconPlus sign icon
Aceragen's email format typically follows the pattern of . Find more Aceragen email formats with LeadIQ.

How much funding has Aceragen raised to date?

Minus sign iconPlus sign icon
As of August 2024, Aceragen has raised $35M in funding. The last funding round occurred on May 03, 2021 for $35M.

When was Aceragen founded?

Minus sign iconPlus sign icon
Aceragen was founded in 2021.
Aceragen

Aceragen

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Aceragen is a rare disease biopharmaceutical company. We address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. As such, the needs of the patients who suffer from neglected rare diseases drive our mission first-and-foremost. Our goal is to provide rare-disease patients with compelling new therapeutic options that will allow them to lead the fullest lives possible. Such diseases have been frequently overlooked for drug development and remain “orphan” due to the assumption that they have a small individual footprint. We aim to change this outlook, engaging in community awareness, regulatory outreach, and most importantly, delivering novel treatments. By focusing on rare and orphan diseases, we hope to bring a much-needed spotlight to the area by leveraging our collective conviction that these efforts will change the world for the better.

Section iconCompany Overview

Headquarters
15 TW Alexander Dr Durham, North Carolina 27709 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ACGN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.